Navigation path

TIP-VAC


HIV/AIDS

Explaining and Improving Efficacy of Targeted Immunodeficiency Virus-like Particle Vaccines against AIDS
Framework programme:
6
Call:
2
Project number:
LSHP-CT-2004-012116
EC contribution:
€ 951,650
Duration:
24 months
Type:
STREP
Starting date:
1 January 2005

Keywords: AIDS; HIV; vaccine; protection

Summary:

With support from two successive EU sponsored consortia (Fifth Framework Programme), we have developed a targeted immunodeficiency virus-like particle vaccine (VLP), which has a heterologous viral surface protein incorporated in the membrane of the particle. This should increase uptake and presentation of VLPs by dendritic cells. A pilot vaccination experiment in the SIV/macaque model provided strong protection against challenge with a pathogenic SIV. Given the urgent need for an HIV vaccine, the potential of this innovative vaccine approach should be evaluated as quickly as possible. Therefore, the aims of the current STREP application of the consortium are 1) to determine the efficacy of the VLPs in a larger number of animals, 2) to understand better the requirements for and the mechanisms of protection, and 3) to further improve the targeted VLPs. The STREP should thus also provide critical information to design evidence-based phase I/II clinical trials with targeted VLPs.

[+] Read More